P3 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso) for the Treatment of Post-Operative Pain in Patients After Knee or Hip Replacement Surgery
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Sufentanil (Primary)
- Indications Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors AcelRx Pharmaceuticals
- 01 Aug 2017 According to an AcelRx Pharmaceuticals media release, the company intends to submit results from IAP312 study together with results of phase 3 studies (IAP309, IAP310 and IAP311) as part of resubmission of a New Drug Application to the FDA by the end of 2017.
- 03 Aug 2015 AcelRx Pharmaceuticals has been granted a General Advice meeting with the U.S. FDA in early September to discuss the FDA's request for a clinical trial and the company's planned response to the Complete Response Letter issued by the FDA for the NDA for Zalviso.
- 02 Jul 2015 According to AcelRx Pharmaceuticals media release, results have been published in Anesthesiology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History